Symbol="NRIX"
AssetType="Common Stock"
Name="Nurix TherapeuticsÂ Inc"
Description="Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California."
CIK="1549595"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, US"
FiscalYearEnd="November"
LatestQuarter="2023-05-31"
MarketCapitalization="464649000"
EBITDA="-159600992"
PERatio="None"
PEGRatio="None"
BookValue="5.46"
DividendPerShare="0"
DividendYield="0"
EPS="-2.91"
RevenuePerShareTTM="1.144"
ProfitMargin="-2.584"
OperatingMarginTTM="-2.71"
ReturnOnAssetsTTM="-0.277"
ReturnOnEquityTTM="-0.598"
RevenueTTM="60935000"
GrossProfitTTM="-145870000"
DilutedEPSTTM="-2.91"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.683"
AnalystTargetPrice="27.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="14.31"
PriceToBookRatio="1.701"
EVToRevenue="6.41"
EVToEBITDA="-1.536"
Beta="1.625"
num_52WeekHigh="19.91"
num_52WeekLow="8.34"
num_50DayMovingAverage="10.19"
num_200DayMovingAverage="10.8"
SharesOutstanding="48200100"
DividendDate="None"
ExDividendDate="None"
symbol="NRIX"
open="9.59"
high="9.71"
low="9.53"
price="9.56"
volume="248288.00"
latest_trading_day="2023-07-25"
previous_close="9.64"
change="-0.08"
change_percent="-0.8299%"
aroon_positive_momentum_days="64"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="64"
Volume_recent_avg="351565"
Change_recent_avg="-0.02"
Delta_recent_avg="0.65"
Variance_recent_avg="0.32"
Change_ratio_recent_avg="-0.27"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="64"
Aroon_momentum_negative="36"
image_negative_thumbnail_id_1="112"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0064.jpeg"
image_negative_thumbnail_id_2="131"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0045.jpeg"
image_neutral_thumbnail_id_1="534"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0065.jpeg"
image_neutral_thumbnail_id_2="524"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_positive_thumbnail_id_1="646"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0062.jpeg"
image_positive_thumbnail_id_2="691"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0017.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
